Myasthenia Gravis Research Highlights: AAN 2024
Released On
June 15, 2024
Expires On
June 30, 2025
Media Type
Internet
Completion Time
30 minutes
Specialty
Neurology, Ophthalmology, Primary Care
Topics
Parkinson's & Movement Disorders
This activity is jointly provided by American Academy of CME, Inc. and CheckRare CE.
This activity is supported by an independent educational grant from argenx US, Inc. and UCB Inc.
Credit Available
- Physicians - maximum of 0.50 AMA PRA Category 1 Credits™
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology and family practice. Other members of the care team may also participate.
Program Overview
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently five drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, rozanolixizumab, and zilucoplan. Clinical trial data on these therapies, as well as real world data, were presented at the American Academy of Neurology Annual Meeting (AAN 2024) held in Denver, CO.
This CME activity, hosted by Nicholas Silvestri, MD, of the University of Buffalo, provides an overview of the latest clinical research presented at AAN 2024 focused on myasthenia gravis.
Learning Objectives
After participating in the activity, learners should be better able to:
- Describe the latest research being presented to better manage people with myasthenia gravis and its clinical relevance
Faculty
Nicholas Silvestri, MD
Professor of NeurologyUniversity of Buffalo Jacobs School of Medicine and Biomedical Sciences
Accreditation Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Credit Designation
American Academy of CME, Inc., designates this enduring material for a maximum of 0.50AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Financial Relationships
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of relevant financial relationships are as follows:
- Nicholas Silvestri, MD discloses the following relevant financial relationships with ineligible companies:
- Advisory Board: argenx, Alexion, UCB, Immunovant, Janssen, Amgen
- Speakers Bureau : argenx, Alexion, UCB, Takeda
Planners for this activity have no relevant financial relationships with any ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the post-test (achieving a passing score of 70%) and the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
American Academy of CME, Inc. requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. This activity will review off-label or investigational information.
Disclaimer
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Contact Information
For CME questions please contact: [email protected].